Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
IO Biotech is a clinical-stage biopharmaceutical company pioneering the discovery and development of novel, immune-modulating T-win® technology-based cancer therapies. The company is focused on activating the patient's own immune system to recognize and eradicate cancer cells. IO Biotech's lead candidates, IO102 and IO103, are designed to target immunosuppressive mechanisms mediated by IDO and PD-L1, respectively, and are being evaluated in clinical trials for various cancer indications, including in combination with anti-PD-1 checkpoint inhibitors.
Serves as the central hub for IO Biotech's research and development, clinical operations, corporate strategy, and administrative functions, guiding the company's global efforts in immuno-oncology.
Located within the Copenhagen Bio Science Park (COBIS), a leading life science cluster, offering access to advanced research infrastructure, collaborative networks, and a dynamic innovation ecosystem.
A dynamic, science-focused, and collaborative work culture prevails, with employees dedicated to advancing innovative cancer therapies. Emphasis is placed on teamwork, scientific rigor, and a patient-first mindset.
The Copenhagen headquarters is strategically important, leveraging Denmark's strong biotech sector and facilitating R&D, clinical development, and partnerships within Europe and globally.
IO Biotech maintains a focused global presence, primarily centered around its research and development operations in Denmark and its clinical and business operations in the United States. The company supports global clinical trials across multiple countries in North America and Europe, collaborating with leading research institutions and contract research organizations (CROs) worldwide to advance its pipeline of novel immuno-oncology therapies.
Ole Maaløes Vej 3
Copenhagen N
Capital Region of Denmark
Denmark
Address: 55 Broad Street, Suite 220, New York, NY 10004
To establish a strong operational footprint in the United States, facilitating clinical development, regulatory interactions, access to capital markets, and strategic collaborations essential for IO Biotech's growth and the advancement of its therapies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, IO Biotech' leadership includes:
IO Biotech has been backed by several prominent investors over the years, including:
Over the past 12 months (May 2023 - May 2024), IO Biotech has made significant leadership appointments, including a new Chief Medical Officer in May 2023 and a new Chief Scientific Officer in September 2023. These changes underscore the company's commitment to advancing its clinical programs. The transition in the Chief Scientific Officer role also occurred during this period.
Discover the tools IO Biotech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
IO Biotech commonly uses the [first].[last]@iobiotech.com email format for its employees. While other formats might exist in smaller numbers, this is the most prevalent pattern observed.
[first].[last]@iobiotech.com
Format
mai-britt.zocca@iobiotech.com
Example
75%
Success rate
GlobeNewswire • May 8, 2024
IO Biotech reported its Q1 2024 financial results, highlighting progress in its clinical trials, including the pivotal Phase 3 trial for IO102-IO103 in combination with pembrolizumab for metastatic melanoma, and outlined key upcoming milestones....more
GlobeNewswire • April 2, 2024
IO Biotech presented promising new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2024, showcasing innovative strategies to boost the immune system's ability to fight tumors, further supporting its T-win technology platform....more
GlobeNewswire • February 28, 2024
IO Biotech reported its full-year 2023 financial results and provided a comprehensive update on its corporate strategy, clinical trial advancements for its lead candidates IO102-IO103, and anticipated developments for 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including IO Biotech, are just a search away.